| 前收市價 | 22.04 |
| 開市 | 22.99 |
| 買盤 | 22.88 x 200 |
| 賣出價 | 22.95 x 400 |
| 今日波幅 | 22.74 - 23.70 |
| 52 週波幅 | 19.65 - 79.38 |
| 成交量 | |
| 平均成交量 | 626,303 |
| 市值 | 1.232B |
| Beta 值 (5 年，每月) | 0.24 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.76 |
| 業績公佈日 | 2024年5月08日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 66.77 |
ZacksEarnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investor's Business DailyRace To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
ZacksCHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
